LQTS004Cx, LQT004Cx
NUIGi005-C
General
Donor Information
General Donor Information |
|
Sex | female |
Age of donor (at collection) | 35-39 |
Ethnicity | Caucasian |
Phenotype and Disease related information (Donor) |
|
Diseases | A disease was diagnosed.
|
Donor Relations |
|
Other cell lines of this donor | |
External Databases (Donor) |
|
BioSamples | SAMEA5912489 |
Ethics
Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
Was the consent voluntarily given? | Yes |
Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
Can you provide us with a copy of the Donor Information Sheet provided to the donor? | Yes |
Do you (Depositor/Provider) hold the original Donor Consent Form? | No |
If you do not hold the Donor Consent Form, do you know who does? | No |
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | pseudonymised |
Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
How may genetic information associated with the cell line be accessed? | No information |
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
Name of accrediting authority involved? | Research Ethics Committee of Galway University Hospitals |
Approval number | C.A.750 |
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? | Yes |
Name of accrediting authority involved? | Research Ethics Committee of Galway University Hospitals |
Approval number | C.A.750 |
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
hIPSC Derivation
General |
|
Source cell type |
Dermal fibroblasts are the major cell type in dermis and are commonly accepted as terminally differentiated cells.
|
Age of donor (at collection) | 35-39 |
Collected in | 2016 |
Reprogramming method |
|
Vector type | Non-integrating |
Vector | Sendai virus |
Vector free reprogramming |
|
Other |
|
Derived under xeno-free conditions |
Unknown |
Derived under GMP? |
Unknown |
Available as clinical grade? |
Unknown |
Culture Conditions
Surface coating | Matrigel/Geltrex |
Feeder cells |
No |
Passage method |
Enzyme-free cell dissociation
Gentle Cell Dissociation Reagent
|
Medium |
Essential 8™ Flex
|
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation
Analysis of Undifferentiated Cells
Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
Alkaline Phosphatase |
Yes |
|
||||
POU5F1 (OCT-4) |
Yes |
|
||||
SOX2 |
Yes |
|
||||
NANOG |
Yes |
|
Differentiation Potency
Microbiology / Virus Screening |
|
Mycoplasma | Negative |
Genotyping
Karyotyping (Cell Line) |
|
Has the cell line karyotype been analysed? |
Yes
No gross chromosomal alterations detected
Karyotyping method:
Molecular karyotyping by SNP array
|
Other Genotyping (Cell Line) |
Login to share your feedback, experiences or results with the research community.